Related Experiment Video
Updated: May 10, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Updates in the Management of HIV During Pregnancy
Jemma Benson1, Cassandra Pierre1, Naima T Joseph2
1Division of Infectious Disease, Department of Medicine, Boston University School of Medicine.
None:
Human immunodeficiency virus in pregnant people remains a significant public health issue worldwide. The rate of perinatal transmission is 15% to 40% but can be decreased to less than 1% with appropriate antenatal management. Previous recommendations included a protease inhibitor-based antiretroviral therapy, infant prophylaxis, performance of cesarean section for uncontrolled viremia, and the use of formula for infant feeding. However, recent updates include first line of integrase inhibitor-based regimens and supporting parental choices for safe lactation. In this review, we summarize and provide updated recommendations for the care of people living with human immunodeficiency virus during pregnancy.
Related Concept Videos
Retrovirus Life Cycles
Teratogenicity
Sexually Transmitted Infections
Therapeutic Drug Monitoring: Affecting Factors
Pharmacokinetics in Pediatric Patients: Drug Excretion
Cytomegalovirus Disease

